Select acquires remainder of subsidiaries
Tuesday, 30 November, 2004
Select Vaccines (ASX: SLT) will acquire the remaining 35 per cent of its two subsidiaries Picoral and Hepgenics from the Burnet Institute.
The institute will be issued 4 million new shares plus 2 million options in Select Vaccines in return for its equity.
Ongoing R&D programs being conducted by the Burnet Institute for the two companies will continue to be funded through December 2005.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...